ASX - By Stock
|
MSB |
Re:
Ann: FDA Grants Orphan Drug Designation for Revascor
|
|
Phaedrus
|
274 |
112K |
15 |
29/03/24 |
29/03/24 |
ASX - By Stock
|
274
|
112K
|
15
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Grants Orphan Drug Designation for Revascor
|
|
Phaedrus
|
274 |
112K |
6 |
29/03/24 |
29/03/24 |
ASX - By Stock
|
274
|
112K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Grants Orphan Drug Designation for Revascor
|
|
Phaedrus
|
274 |
112K |
40 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
274
|
112K
|
40
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
Phaedrus
|
1.0K |
453K |
10 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
1.0K
|
453K
|
10
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
Phaedrus
|
1.0K |
453K |
4 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
1.0K
|
453K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Grants Orphan Drug Designation for Revascor
|
|
Phaedrus
|
274 |
112K |
35 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
274
|
112K
|
35
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Phaedrus
|
943 |
417K |
1 |
27/03/24 |
27/03/24 |
ASX - By Stock
|
943
|
417K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Phaedrus
|
943 |
417K |
9 |
27/03/24 |
27/03/24 |
ASX - By Stock
|
943
|
417K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Phaedrus
|
943 |
417K |
6 |
27/03/24 |
27/03/24 |
ASX - By Stock
|
943
|
417K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Phaedrus
|
943 |
417K |
5 |
27/03/24 |
27/03/24 |
ASX - By Stock
|
943
|
417K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Phaedrus
|
943 |
417K |
9 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
943
|
417K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
Phaedrus
|
1.0K |
453K |
1 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
1.0K
|
453K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
Phaedrus
|
1.0K |
453K |
7 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
1.0K
|
453K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
Phaedrus
|
1.0K |
453K |
46 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
1.0K
|
453K
|
46
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
Phaedrus
|
1.0K |
453K |
34 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
1.0K
|
453K
|
34
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
Phaedrus
|
1.0K |
453K |
29 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
1.0K
|
453K
|
29
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
Phaedrus
|
1.0K |
453K |
44 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
1.0K
|
453K
|
44
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Pause in Trading
|
|
Phaedrus
|
226 |
86K |
5 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
226
|
86K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Pause in Trading
|
|
Phaedrus
|
226 |
86K |
11 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
226
|
86K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Pause in Trading
|
|
Phaedrus
|
226 |
86K |
8 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
226
|
86K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Pause in Trading
|
|
Phaedrus
|
226 |
86K |
7 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
226
|
86K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Pause in Trading
|
|
Phaedrus
|
226 |
86K |
5 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
226
|
86K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Pause in Trading
|
|
Phaedrus
|
226 |
86K |
3 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
226
|
86K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Pause in Trading
|
|
Phaedrus
|
226 |
86K |
11 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
226
|
86K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Phaedrus
|
18K |
7.1M |
15 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
18K
|
7.1M
|
15
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Phaedrus
|
943 |
417K |
37 |
25/03/24 |
25/03/24 |
ASX - By Stock
|
943
|
417K
|
37
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Phaedrus
|
943 |
417K |
8 |
23/03/24 |
23/03/24 |
ASX - By Stock
|
943
|
417K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Phaedrus
|
943 |
417K |
19 |
23/03/24 |
23/03/24 |
ASX - By Stock
|
943
|
417K
|
19
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Phaedrus
|
943 |
417K |
24 |
23/03/24 |
23/03/24 |
ASX - By Stock
|
943
|
417K
|
24
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Phaedrus
|
943 |
417K |
20 |
23/03/24 |
23/03/24 |
ASX - By Stock
|
943
|
417K
|
20
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
Phaedrus
|
549 |
190K |
26 |
22/03/24 |
22/03/24 |
ASX - By Stock
|
549
|
190K
|
26
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
Phaedrus
|
549 |
190K |
14 |
21/03/24 |
21/03/24 |
ASX - By Stock
|
549
|
190K
|
14
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
Phaedrus
|
549 |
190K |
13 |
21/03/24 |
21/03/24 |
ASX - By Stock
|
549
|
190K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
Phaedrus
|
549 |
190K |
17 |
21/03/24 |
21/03/24 |
ASX - By Stock
|
549
|
190K
|
17
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
Phaedrus
|
549 |
190K |
21 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
549
|
190K
|
21
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
Phaedrus
|
549 |
190K |
25 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
549
|
190K
|
25
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
Phaedrus
|
549 |
190K |
20 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
549
|
190K
|
20
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Change in substantial holding
|
|
Phaedrus
|
85 |
24K |
1 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
85
|
24K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Change in substantial holding
|
|
Phaedrus
|
85 |
24K |
13 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
85
|
24K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Change in substantial holding
|
|
Phaedrus
|
85 |
24K |
12 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
85
|
24K
|
12
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Change in substantial holding
|
|
Phaedrus
|
85 |
24K |
34 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
85
|
24K
|
34
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Phaedrus
|
18K |
7.1M |
6 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
18K
|
7.1M
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Phaedrus
|
18K |
7.1M |
20 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
18K
|
7.1M
|
20
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Phaedrus
|
18K |
7.1M |
6 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
18K
|
7.1M
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Phaedrus
|
18K |
7.1M |
17 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
18K
|
7.1M
|
17
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Phaedrus
|
18K |
7.1M |
10 |
19/03/24 |
19/03/24 |
ASX - By Stock
|
18K
|
7.1M
|
10
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Phaedrus
|
18K |
7.1M |
29 |
19/03/24 |
19/03/24 |
ASX - By Stock
|
18K
|
7.1M
|
29
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Cleansing Notice
|
|
Phaedrus
|
5 |
2.8K |
10 |
19/03/24 |
19/03/24 |
ASX - By Stock
|
5
|
2.8K
|
10
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Phaedrus
|
18K |
7.1M |
13 |
19/03/24 |
19/03/24 |
ASX - By Stock
|
18K
|
7.1M
|
13
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Phaedrus
|
18K |
7.1M |
25 |
19/03/24 |
19/03/24 |
ASX - By Stock
|
18K
|
7.1M
|
25
|
|